glp-1 intestinal paralysis lawsuit in kentucky Kentucky's Conflicting Signals on Compounded

Suggested Caption: On November 26, 2024, the Centers for Medicare &amp

The US Food and Drug Administration on Monday approved a generic version of the daily injectable GLP-1 medicine liraglutide for people with type 2 diabetes, opening the door for lower-priced options to reach the market and help address a shortage.

David Kessler says the new weight-loss drugs are a powerful tool to fight obesity

Whats included

These milestones will redefine how obesity care is delivered, marking a turning point that will shape the markets trajectory for 2026 and the years to come

Background Limited data are available on the risk of pancreatic adverse events among people with obesity or type 2 diabetes mellitus (T2DM) initiating glucagon-like peptide-1 receptor agonist (GLP-1 RA)